1-8 of 8
Christina To
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

Clinical Trials & Observations
Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P. Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Journal: Blood
Blood (2024) 143 (24): 2464–2473.
https://doi.org/10.1182/blood.2023021620
Published: 2024
Includes: Supplemental data
Journal Articles

An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts

Sandeep Raj, Jin Xie, Teng Fei, Qinghua Song, Jenny J. Kim, Christina To, Marcel R.M. van den Brink, Miguel-Angel Perales, Mike Mattie, Roni Shouval
Journal: Blood
Blood (2023) 142 (Supplement 1): 224.
https://doi.org/10.1182/blood-2023-173798
Published: 2023
Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Marie José Kersten, Umar Farooq, Aaron P. Rapoport, Frederick L. Locke, Lori A. Leslie, Armin Ghobadi, David B. Miklos, Caron A. Jacobson, Javier L. Munoz, Patrick B Johnston, Samantha M. Jaglowski, Ian W. Flinn, Tom van Meerten, Miguel-Angel Perales, Peter Vandenberghe, Peter A. Riedell, Kathleen Dorritie, David Szwajcer, Dimitrios Tzachanis, Saran Vardhanabhuti, Linqiu Du, Simone Filosto, Shilpa A. Shahani, Christina To, Jason Westin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1761.
https://doi.org/10.1182/blood-2023-173873
Published: 2023
Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Clinical Trials & Observations
Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Journal: Blood
Blood (2022) 140 (21): 2248–2260.
https://doi.org/10.1182/blood.2022015478
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, Javier Munoz, Jason Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 1595–1597.
https://doi.org/10.1182/blood-2022-158303
Published: 2022
Journal Articles

Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P Rowe, Saran Vardhanabhuti, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Journal: Blood
Blood (2022) 140 (Supplement 1): 638–640.
https://doi.org/10.1182/blood-2022-158492
Published: 2022
Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Christina To, Marie José Kersten
Journal: Blood
Blood (2021) 138 (Supplement 1): 430.
https://doi.org/10.1182/blood-2021-147598
Published: 2021
Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron Jacobson, Miguel-Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom Van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin
Journal: Blood
Blood (2021) 138 (Supplement 1): 2.
https://doi.org/10.1182/blood-2021-148039
Published: 2021